Novo Nordisk: files diabetes drug for obesity control in US
(CercleFinance.com) - Denmark's Novo Nordisk said on Friday that it has filed its diabetes drug semaglutide for approval in the US for chronic weight management.
The company said a late-stage trial including more than 4,500 adults with obesity or overweight showed a weight loss of 15-18% for people treated with semaglutide.
The potential indication is for the treatment of adults with obesity, or who are overweight, with at least one weight-related comorbidity, as an adjunct to diet and physical activity, Novo said in a statement.
The Danish drugmaker said a priority review status has been applied to the filing, meaning the FDA will have to review the medicine in six months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company said a late-stage trial including more than 4,500 adults with obesity or overweight showed a weight loss of 15-18% for people treated with semaglutide.
The potential indication is for the treatment of adults with obesity, or who are overweight, with at least one weight-related comorbidity, as an adjunct to diet and physical activity, Novo said in a statement.
The Danish drugmaker said a priority review status has been applied to the filing, meaning the FDA will have to review the medicine in six months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.